|
|
|
June 11, 2012 | Genentech announced early results of a new drug targeting HER2-expressing cancers early last week, and later received FDA approval to market Perjeta in combination with Herceptin and Taxotere. About one-fourth of women with breast cancer in the US would be candidates for the combination treatment. Xconomy
|
|
|